Multiple Myeloma and Other Plasma Cell Neoplasms (Record no. 28997)

MARC details
000 -LEADER
fixed length control field 02287nam a22003137a 4500
001 - CONTROL NUMBER
control field 20241001131259.0
003 - CONTROL NUMBER IDENTIFIER
control field 20241001131259.0
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20241001131741.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 241001b |||||||| |||| 00| 0 eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 978-3-319-25584-2
International Standard Book Number 978-3-319-25586-6
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 2197-9766
International Standard Serial Number 2197-9774
040 ## - CATALOGING SOURCE
Transcribing agency ddc
041 ## - LANGUAGE CODE
Language code of text/sound track or separate title English
082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.994 15 DIM
100 ## - MAIN ENTRY--PERSONAL NAME
Fuller form of name Meletios A. Dimopoulos
245 ## - TITLE STATEMENT
Title Multiple Myeloma and Other Plasma Cell Neoplasms
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Athens Greece |
Name of publisher, distributor, etc. Springer International Publishing Switzerland |
Date of publication, distribution, etc. 2018.
300 ## - PHYSICAL DESCRIPTION
Extent 247 Pages
Extent Includes References
490 ## - SERIES STATEMENT
Series statement https://doi.org/10.1007/978-3-319-25586-6
Volume/sequential designation Hematologic Malignancies
520 ## - SUMMARY, ETC.
Summary, etc. This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management.
600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME
General subdivision Hematology, Immunology, Medical / Clinical Medicine, Medical / Hematology, Medical / Immunology, Medical / Oncology / General, Oncology, Medicine, Medicine and Public Health, Multiple myeloma.
700 ## - ADDED ENTRY--PERSONAL NAME
Fuller form of name Thierry Facon
Fuller form of name Evangelos Terpos
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href=" https://doi.org/10.1007/978-3-319-25586-6 "> https://doi.org/10.1007/978-3-319-25586-6 </a>
Link text https://doi.org/10.1007/978-3-319-25586-6
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme ddc
Koha item type E-BOOKS
Suppress in OPAC
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Date acquired Total checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO 10/01/2024   616.994 15 DIM 20241001131259.0 10/01/2024 10/01/2024 E-BOOKS
Catholic University of  Health and Allied Sciences - CUHAS
Directorate of ICT @ 2024